Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02072044
- Locations
- 🇨🇳
Cancer Hospital of Fudan University, Shanghai, Shanghai, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT02029209
- Locations
- 🇨🇳
20th Floor, Block C, Lake Road, Hexi District, Tianjin Medical University Cancer Institute and Hospital ., Tianjin, Tianjin, China
Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）
- Conditions
- Interventions
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT01924195
- Locations
- 🇨🇳
Hunan Province Tumor Hospital, Changsha, Hunan, China
🇨🇳Shanghai Changhai Hospital, Shanghai, Shanghai, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Phase II Study of Anlotinib in STS Patients
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 166
- Registration Number
- NCT01878448
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳Fujian Province Cancer Hospital, Fuzhou, Fujian, China
A Phase II Study of Anlotinib in MTC Patients
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 58
- Registration Number
- NCT01874873
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The first hospital affiliated to fujian medical university, Fuzhou, Fujian, China
🇨🇳Gansu Province Tumor Hospital, Lanzhou, Gansu, China
A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT01833923
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.